Sign Out
Early Breast Cancer (EBC): Phesgo is indicated in combination with chemotherapy for the: neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer (see Pharmacology: Pharmacodynamics: Clinical/efficacy studies under Actions); adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence (see Pharmacology: Pharmacodynamics: Clinical/efficacy studies under Actions).
Metastatic Breast Cancer (MBC): Phesgo is indicated in combination with docetaxel for adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Continue with Google